Apellis Pharmaceuticals, Inc.

This study tested the long-term safety and effectiveness of pegcetacoplan in 792 people with geographic atrophy, a form of advanced dry age-related macular degeneration that causes vision loss. Participants had previously been in earlier pegcetacoplan trials. The goal was to see …

This study tested the long-term safety of a drug called pegcetacoplan in people with PNH, a rare blood disease that destroys red blood cells. All 137 participants had already completed a prior pegcetacoplan study and continued treatment. The main goal was to track side effects ov…

This phase 2 study tested a drug called pegcetacoplan in 13 kidney transplant patients whose original kidney disease (C3G or IC-MPGN) had come back. The goal was to see if the drug could reduce signs of disease activity in the kidney. The study was small and early-stage, so resul…

This study tested a drug called pegcetacoplan in 124 adults and teens with two rare kidney diseases (C3G and IC-MPGN). The goal was to see if the drug could reduce protein in the urine, a sign of kidney damage. Participants received either the drug or a placebo twice a week for 2…

This study tested a drug called pegcetacoplan, given as an eye injection using a prefilled syringe, in 44 people with geographic atrophy (a form of advanced age-related macular degeneration). The main goal was to see if the new syringe is safe and easy for doctors to use. The dru…